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Recommendations for legislators and policymakers
Legislators and other policymakers play a critical
role in ensuring that resources are adequate to
achieve the nation’s HPV vaccination goals.
Suggestions for legislators and other policymakers
include:
1. Advocate for improved administration authori-
ty, insurance coverage (including Medicaid),
and reimbursement rates to healthcare pro-
viders who make HPV vaccine available to
adolescents in a variety of settings
2. Provide instrumental support to fund the
development of school curricula on HPV
vaccination that will:
a. Optimize school health education oppor-
tunities
b. Enhance the role of schools in parent and
community education, vaccine adminis-
tration, and other vaccination-related ac-
tivities
3. Increase public awareness that HPV vaccina-
tion can prevent cancer
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BOTTOMLINE:
The content of this Policy Brief have not been previously published and manuscript has not been submitted elsewhere.
Implications
Practice: Healthcare providers and healthcare systems should improve
patient education and communication, clinical standards of practice, and
information systems to ensure eligible female and male patients initiate
and complete the full HPV vaccination series.
Policy: Legislators and policy makers should ensure adequate resources
to achieve the HPV vaccination goals by advocating for improved
coverage and reimbursement for providers, optimized school curricula
and role in vaccination-related activities, and increased public awareness.
Research: SBM encourages the initiation of studies employing
implementation science methodologies to identify behavioral and
systems strategies for addressing both supply-side and demand side
barriers to HPV vaccination uptake and series completion
BACKGROUND
Human papillomavirus (HPV) infection is common in the USA and
globally. The Centers for Disease Control and Prevention estimates that
14 million new infections occur annually in the USA [1]. Approximately
26,000 new cancers in the USA are attributable to HPV annually [2]. The
virus affects both males and females through its association with oral
cancer, anal cancer, and genital warts. HPV infection also causes cervical
[3, 4], vulvar, and vaginal cancers in women and penile cancer in men [5–
8]. It is notable that 39 % of all HPV-related cancers occur in males [9],
and the incidence of HPV-related oral cancers has rapidly increased in this
population since 2000 [10]. Furthermore, HPV-associated illnesses con-
tribute significantly to the US healthcare expenditures. Yearly costs to treat
HPV-related diseases in the USA are estimated at $8 billion [11].
NEED FOR IMPROVED HPV VACCINE COVERAGE FOR CANCER PREVENTION
HPV vaccination is an effective primary prevention strategy to reduce
infections that can lead to cancer [12]. The HPV vaccines available in the
USA [13–15] currently require three doses over a 6-month period. The US
Advisory Committee on Immunization Practices and the American
Academy of Pediatrics recommend routine vaccination for females and
males ages 11–12 years. The recommendations also permit late vaccina-
tion of females and males up to 26 and 21 years, respectively. [16, 17].
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Recommendations for healthcare providers/healthcare
systems
All healthcare providers, including primary care,
hospital care, and nontraditional care providers
(e.g., schools, pharmacies, and public health
departments) can contribute to increasing HPV
vaccination coverage. Suggestions for these pro-
viders include:
1. Increase the strength, quality, and consistency
of HPV vaccination recommendations for all
eligible patients, focusing on patients ages 11
and 12
2. Treat HPV vaccination as a routine preven-
tive service like other ACIP-recommended
vaccines [20]
3. Address hesitancy by employing culturally
appropriate communication strategies with
patients, parents, and guardians and
responding effectively to common concerns
about the importance, effectiveness, and safety
of HPV vaccination
4. Strengthen and coordinate the use of electron-
ic medical records and immunization infor-
mation systems to:
a. Identify eligible patients for first dose
initiation [30] or series completion
b. Provide access to patient immunization
records across patient care providers,
vaccine administrators, and the state pub-
lic health system
NEED FOR IMPROVED HPV VACCINE COVERAGE
HPV vaccines are both effective and safe [18, 19], yet vaccination
coverage remains low. National data from 2014 indicate that, 60 % of
eligible females and 42 % of eligible males have received an initial dose.
Fewer than 40 % of eligible females and fewer than 22 % of eligible males
have completed the three-dose series [20]. Nationally, the median HPV
vaccination coverage rates for female adolescents among commercial and
Medicaid plans in 2013 were 12 and 19 %, respectively [21].
Three important factors that contribute to poor vaccine uptake are
amenable to change. Many healthcare providers miss opportunities to
recommend and administer the vaccine, [22–24] in part due to absent or
low-quality recommendations [25]. Significant parental barriers exist,
including parents’ concerns about vaccine safety and cost, lack of
knowledge, and failure to receive a provider recommendation [26–28].
In addition, access to HPV vaccination services are limited for some
populations and in some geographic areas [11, 26].
BUILDING CONSENSUS TO INCREASE HPV VACCINE UPTAKE
The US Department of Health and Human Services Healthy People 2020
goals (IID-11.4/5) include increasing vaccination coverage with three
doses of HPV vaccine among females and males ages 13 to 15 years, with
a target of 80 % [29]. The President’s Cancer Panel (PCP) and the National
Vaccine Advisory Committee have also urged the nation to increase
vaccine coverage. The PCP 2014 report established four goals to increase
HPV vaccine uptake: (1) reduce missed clinical opportunities to recom-
mend and administer the vaccine, (2) increase parents’, caregivers’, and
adolescents’ acceptance of the vaccine, (3) maximize access to HPV
vaccination services, and (4) promote global HPV vaccine uptake [11]. In
2016, the National Vaccine Advisory Committee endorsed the PCP goals
and made three additional recommendations: (1) develop evidence-based,
effective, coordinated communication strategies, (2) strengthen the systems
that support immunization, and (3) support the simplest HPV immuniza-
tion schedule [3].
SUMMARY AND RECOMMENDATIONS
HPV infection is widespread and increases the risk for cancers in both
males and females. Despite effectiveness of HPV vaccination, coverage is
low. Improving vaccination coverage involves both increasing the number
of eligible males and females receiving the initial vaccine dose (initiation)
and ensuring that the series is completed (completion) [11]. We support the
goals outlined by Healthy People 2020, the President’s Cancer Panel, and
the National Vaccine Advisory Committee, which suggest actions that will
result in a healthier public. These actions aim to increase initiation of HPV
vaccination and reduce the structural barriers to vaccination services in
order to increase series completion. Specifically, The Society of Behavioral
Medicine (SBM) recommends legislators, policymakers, healthcare pro-
viders, and healthcare systems to consider the policy-related and clinical
implications related to HPV regulation and uptake described herein.
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